KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS + IMD) in Pediatric Outpatients With COVID-19.

Thomas D Norton, Mazhar Thakur, Samit Ganguly, Shazia Ali, Jesse Chao, Alpana Waldron, Jing Xiao, Kenneth C Turner, John D Davis, Susan C Irvin, Cynthia Pan, Dominique Atmodjo, Andrea T Hooper, Jennifer D Hamilton, Mohamed Hussein, Danise Subramaniam, Lilia Roque-Guerrero, Anita Kohli, Eleftherios Mylonakis, Gregory P Geba, Edward Cox, Ned Braunstein, Paula Dakin, Bari Kowal, Rafia Bhore, A Thomas DiCioccio, Diana Hughes, Gary A Herman, Trial Investigators

J Pediatric Infect Dis Soc 13(11) 589-593

PMID39351798
PMCIDPMC11599144
DOI10.1093/jpids/piae105
发表日期2024-10-01
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

The safety of casirivimab + imdevimab (CAS + IMD) (anti-severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] monoclonal antibodies [mAbs]) in pediatric outpatients with coronavirus disease 2019 (COVID-19) was evaluated in a randomized phase 1/2/3 trial. Consistent with adults, CAS + IMD was generally well tolerated with low drug-induced immunogenicity rates. The findings support the development of next-generation anti-SARS-CoV-2 mAbs for at-risk pediatric patients.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。